BioMérieux Receives Prestigious Frost & Sullivan 2008 North American Market Leadership Award For Pharmaceutical Microbiology

Main Category: Pharma Industry / Biotech Industry
Article Date: 15 Oct 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology. bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraints, brand recognition as well as strategy development and methods of addressing market trends.

bioMérieux ranked highest in 3 out of 4 categories, which included market positioning and growth, innovative performance, growth strategy, and leveragable assets. The company's overall score was more than two points higher than the combined average score of the other Tier I companies evaluated. bioMérieux was also acknowledged for its unparalleled product quality and customer support in the industry, noting that bioMérieux systems offer automated solutions that increase workflow and reduce employee training times.

"Delivering rapid testing methods to help our biopharma customers ensure the quality of their manufacturing processes is our priority," said Alexandre Mérieux, Corporate Vice President, Industrial Microbiology. "I am honored to see the efforts of our North American team recognized by Frost & Sullivan."

"The shift from traditional culture methods to rapid microbiology testing is critical to address the needs of today's pharmaceutical industry," confirmed Madhu Sharma, Ph.D., Senior Research Analyst at Frost & Sullivan.

The Frost & Sullivan award applauded bioMérieux for continuously enhancing its product offer to meet customer needs. bioMérieux's recent launches include DiversiLab™ Strain Typing systems for same-day investigation results, BioBall® quantitative bacterial cultures and 3PTM clean room and Isolator media.

About the Award

Frost & Sullivan determines the winner of the annual North American Market Leadership Award with a methodology that measures and tracks competitor revenue and market share within the rapid pharmaceutical manufacturing microbiology tests market. The research methodology includes interviews with market participants and secondary research of proprietary data sources. Companies also receive exceptional consideration if they substantially increase market share, revenue growth rates, profitability, or market and technology innovation.

About Frost & Sullivan

Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empowers clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

About bioMérieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at http://www.biomerieux.com and http://www.biomerieux-industry.com

Source:
Koren Wolman-Tardy
bioMérieux